Showing 1–25 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Abidi S, Achar J, Assao Neino MM, Bang D, Benedetti A, et al.
…tiveness of two World Health Organization (WHO)-recommended regimens for the treatment of rifampin- or multidrug-resistant (RR/MDR) tuberculosis (TB): a standardised regimen of 9-12 months (the "shorter regimen") and individualised regimens of ≥20 months ("longer regimens").We co…
Park HY, Kwon JW, Kim HL, Kwon SH, Nam JH, et al.
Background Regimens for the treatment of multidrug-resistant tuberculosis (MDR-TB) have been changed from injectable-containing regimens to all-oral regimens. The economic effectiveness of new all-oral regimens compared with conventional injectable-containing regimens was scarcel…
Budak M, Cicchese JM, Maiello P, Borish HJ, White AG, et al.
…ng more effective and more patient-friendly antibiotic drug regimens to increase patient compliance and decrease emergence of resistant TB. Moxifloxacin is one promising antibiotic that may improve the current standard regimen by shortening treatment time. Clinical trials and in …
Happiness Cornel Mvungi, Peter Masunga Mbelele, Kassim Salim Msaji, Stellah George Mpagama, Hadija Hamis Semvua
… Health Organization recommended all-oral bedaquiline-based regimens, but evidence comparing their effectiveness to injectable-containing regimens is limited. This study evaluated treatment success between both approaches. **METHODS:** This was a retrospective study, which inclu…
Zainabadi K, Vilbrun SC, Mathurin LD, Walsh KF, Pape JW, et al.
…g-resistant tuberculosis (DR-TB). How these new second-line regimens fare in comparison to first-line regimens for treatment of drug-sensitive tuberculosis (DS-TB) is not well known. Methods In this study, we contemporaneously enrolled subjects with DS-TB (n = 31) or DR-TB (n = 2…
Ashwin Karnan, Ulhas Jadhav, Babaji Ghewade, Vivek Alone
…reatment. Evaluating the effectiveness of various treatment regimens is crucial for identifying the best balance among treatment duration, efficacy, adverse drug effects, and patient adherence. A prospective, observational study on 50 MDR-TB patients was carried out at a tertiary…
Jefman Efendi Marzuki HY, Nafrialdi N, Sawitri N, Sugiri YJ, Gusti Agung Ayu Putu Sri Darmayani I, et al.
…DR-TB patients on DLM regimen compared to shorter treatment regimens (STR). Methods A retrospective cohort was implemented on secondary data obtained from two participating hospitals. The QTc interval and the changes in QTc interval from baseline (ΔQTc) were assessed every 4 week…
Rosu L, Madan JJ, Tomeny EM, Muniyandi M, Nidoi J, et al.
…he STREAM stage 2 trial assessed two bedaquiline-containing regimens for rifampicin-resistant tuberculosis: a 9-month all-oral regimen and a 6-month regimen containing an injectable drug for the first 2 months. We did a within-trial economic evaluation of these regimens. Methods …
Goodall RL, Nunn AJ, Meredith SK, Bayissa A, Bhatnagar AK, et al.
…round STREAM stage 2 showed that two bedaquiline-containing regimens (a 9-month all-oral regimen and a 6-month regimen with 8 weeks of aminoglycoside) had superior efficacy to a 9-month injectable-containing regimen for rifampicin-resistant tuberculosis up to 76 weeks after rando…
Gu P, Lu P, Ding H, Liu Q, Ding X, et al.
…ound To compare the effectiveness, cost, and safety of four regimens recommended by the World Health Organization (WHO) for rifampicin resistance/multidrug-resistance tuberculosis (RR/MDR-TB) Treatment in Eastern China. Methods We performed a cohort study among patients with RR/M…
Danyuchen Sun, Zhili Li, Yingpeng Qiu, Wei Shu, Lijie Zhang, et al.
…valuate the cost-effectiveness of two novel drug containing regimens compared to traditional regimen in Chinese adult population. **METHODS:** We performed a cost-effectiveness analysis from the perspective of the patient. Clinical treatment information and outcomes were retrosp…
Ding Y, Zhu H, Fu L, Zhang W, Wang B, et al.
…after 8 weeks). In conclusion, oral short-course three-drug regimens, including TBI-166 with high efficacy, were identified. The TBI-166+BDQ+PZA regimen is recommended for further study in a TBI-166 phase IIb clinical trial.
Nsengiyumva NP, Campbell JR, Oxlade O, Vesga JF, Lienhardt C, et al.
…r, and cheaper tuberculosis (TB) preventive treatment (TPT) regimens will enhance uptake and effectiveness. WHO developed target product profiles describing minimum requirements and optimal targets for key attributes of novel TPT regimens. We performed a cost-effectiveness analys…
Nunn AJ, Phillips PPJ, Meredith SK, Chiang CY, Conradie F, et al.
…idrug-resistant tuberculosis who received existing drugs in regimens shorter than that recommended by the World Health Organization (WHO) in 2011. Methods We conducted a phase 3 noninferiority trial in participants with rifampin-resistant tuberculosis that was susceptible to fluo…
Kohler S, Sitali N, Achar J, Paul N
…hs), 10 shorter (9-12 months), and 8 short (≤6 months) drug regimens for drug-sensitive (DS) and multidrug-resistant (MDR)-TB treatment. Costs per regimen were estimated by multiplying recommended drug amounts with 2021 Global Drug Facility prices and drug import costs of a TB pr…
Marcela Muñoz-Torrico, Rafael Laniado-Laborín, Jorge Rojas-Serrano, Eduardo Becerril-Vargas, Wendy Cinecio-Chávez, et al.
…ere mainly related to linezolid use. **CONCLUSIONS:** Oral regimens appear to be effective, although toxicity to linezolid requires strict patient monitoring.
Goodall RL, Meredith SK, Nunn AJ, Bayissa A, Bhatnagar AK, et al.
…EAM stage 2, we aimed to compare two bedaquiline-containing regimens with the 9-month STREAM stage 1 regimen. Methods We did a randomised, phase 3, non-inferiority trial in 13 hospital clinics in seven countries, in individuals aged 15 years or older with rifampicin-resistant tub…
Malaisamy Muniyandi, Balaji Ramraj, Sathishkumar Vadamalai, Sahil Abdul Salam, Bella Devaleenal, et al.
**BACKGROUND:** Short-course regimens are currently explored to improve multidrug-resistant tuberculosis effects, reduce costs, as well as enhance patient adherence. Currently, we are determining the most cost-effective shorter regimen out of seven short-course regimens (6-9 …
Kohler S, Sitali N, Achar J, Paul N
…nd their import are costly. We assessed how shorter TB drug regimens, which were non-inferior or superior in recent TB trials, can affect the costs for purchasing and importing TB drugs. Methods We estimated the drug costs and import costs of 39 longer and shorter TB drug regimen…
Vijay Kumar, G S Sri Bharathi, Mohit Bhatia, Sankha Shubhra Chakrabarti, Upinder Kaur, et al.
…nalyze therapeutic outcomes with bedaquiline-based all-oral regimens for drug-resistant tuberculosis. A prospective observational study was conducted from August 2022 to March 2024 and patients of drug-resistant tuberculosis on all-oral regimens were enrolled. Among 100 patients …
Ryckman TS, Schumacher SG, Lienhardt C, Sweeney S, Dowdy DW, et al.
…tent to which future improvements in tuberculosis treatment regimens could offset potential increases in drug costs. Methods In this modelling analysis, we used an ingredients-based approach to estimate prices at which novel regimens for rifampin-susceptible and rifampin-resistan…
Norbert Ndjeka, Rubeshan Perumal, Kamila Romanowski, Hlengani Mathema, Lateef Babatunde Amusa, et al.
**BACKGROUND:** Shorter all-oral regimens for the treatment of multidrug-resistant tuberculosis or rifampicin-resistant tuberculosis (MDR/RR-TB) have improved efficacy, but their performance under programmatic conditions remains insufficiently characterized. **METHODS:** We retr…
Gupta A, Juneja S, Babawale V, Rustam Majidovich N, Ndjeka N, et al.
…e rollout of new WHO-recommended shorter all-oral treatment regimens for drug-resistant TB (DR-TB), which remains a public-health crisis. The all-oral, 6-month BPaL/M regimen comprises 3-4 drugs: pretomanid used in combination with bedaquiline and linezolid, with or without moxif…
Adriana Chacón, Yamile Celis Bustos, Dany Martinez, Felix Chong, Clara Freile, et al.
…ogrammatic cohort, the nine-month all-oral shorter and BPaL regimens were associated with favorable treatment outcomes, acceptable safety profiles, improved adherence, and reduced loss to follow-up compared with injectable-based therapy. These findings supported Ecuador’s …
Khan PY, Franke MF, Hewison C, Seung KJ, Huerga H, et al.
…le agents, in use for decades, and endorsed all-oral longer regimens. However, questions remain about the role of the injectable agent, particularly in the context of regimens using new and repurposed drugs. We compared the effectiveness of an injectable-containing regimen to tha…